Daejeon, South Korea

Sang Jick Kim

This inventor holds 2 USPTO granted patents, plus 1 CIPO patent and 2 EPO patents. Top assignees: Korea Research Institute of Bioscience and Biotechnology, Snu Rdb Foundation. Active years: 2012-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sang Jick Kim. Retrieved from https://idiyas.com/inventor/sang-jick-kim

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0


 

Average Co-Inventor Count = 7.9

ph-index = 2

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2012-2017

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Sang Jick Kim: Innovator in Monoclonal Antibody Research

Introduction

Sang Jick Kim is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 2 patents, his work focuses on innovative solutions for cancer treatment and diagnosis.

Latest Patents

One of his latest patents is a monoclonal antibody specifically bound to the TM4SF5 protein. This invention relates to a novel monoclonal antibody that targets the human TM4SF5 protein, along with methods for treating liver fibrosis and cancer. Additionally, he has developed humanized anti-TAG-72 monoclonal antibodies, which are designed to enhance antigen binding affinity and are used in anticancer compositions.

Career Highlights

Sang Jick Kim has worked with notable organizations such as the Korea Research Institute of Bioscience and Biotechnology and the Snur & Db Foundation. His research has contributed to advancements in cancer therapies and diagnostic methods.

Collaborations

Throughout his career, he has collaborated with colleagues including Se Mi Kim and Hye Jin Min. These partnerships have furthered his research and development efforts in the field of monoclonal antibodies.

Conclusion

Sang Jick Kim's innovative work in monoclonal antibody research has the potential to significantly impact cancer treatment and diagnosis. His contributions to biotechnology continue to pave the way for future advancements in medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…